Skip to main content
Fig. 4 | Genome Medicine

Fig. 4

From: Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial

Fig. 4

Identification of molecular determinants to ramucirumab response via integrative analysis. a Elastic-net regression results of transcriptome and genomic features that predict clinical response to objective response rate. The bottom scatter plots represent ramucirumab response based on tumor reduction rate. The upper heatmap shows the top extracted features in the model. The left bar graph shows the averaged weight of each predictive feature. The number of appearance from 100 bootstraps is indicated in parentheses. b Predictive features of ramucirumab response identified by the elastic-net regression model-based analysis are plotted based on their appearance frequency and effect size. Associations are colored in red for overall survival, blue for progression-free survival, and green for tumor reduction rate. The averaged weights for all the features that were extracted against tumor reduction rate were plotted inversely to show consistency in clinical prognosis. Node size is proportional to the single clinical-feature linear correlation

Back to article page